Distinct mdm2/p53 expression in patterns in liposarcoma subgroups: Implications for different pathogenetic mechanisms

Journal of Pathology

Volumn 181, Issue 1, 1997, Pages 14-24

  Pilotti, Silvana ^a,d   Della Torre, Gabriella ^b   Lavarino, Cinzia ^a   Di Palma, Silvana ^a   Sozzi, Gabriella ^b   Minoletti, Fabiola ^b   Rao, Stefania ^a   Pasquini, Graziella ^b   Azzarelli, Alberto ^c   Rilke, Franco ^d   Pierotti, Marco A ^b  

^a Div of Anat Pathology and Cytology   (Italy)

^b Div Exp Oncol B   (Italy)

^c Division of General Surgery B   (Italy)

^d NATIONAL CANCER INSTITUTE   (Italy)

Author keywords

immunocytochemistry; liposarcoma; MDM2 gene; mdm2 protein; molecular analysis; p53 protein; pathogenesis; rearrangement; TP53 gene

Indexed keywords

PROTEIN P53;

ADOLESCENT; ADULT; AGED; ARTICLE; CHROMOSOME ABERRATION; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; GENE MUTATION; GENE REARRANGEMENT; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LIPOSARCOMA; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; SOFT TISSUE SARCOMA;

ADOLESCENT; ADULT; AGED; CHROMOSOME ABERRATIONS; FEMALE; GENE EXPRESSION; GENOTYPE; HUMANS; IMMUNOENZYME TECHNIQUES; IMMUNOPHENOTYPING; LIPOMA; LIPOSARCOMA; MALE; MIDDLE AGED; NEOPLASM PROTEINS; NUCLEAR PROTEINS; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-MDM2; RETROPERITONEAL NEOPLASMS; RETROSPECTIVE STUDIES; TUMOR SUPPRESSOR PROTEIN P53;

EID: 0031046598     PISSN: 00223417     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1096-9896(199701)181:1<14::AID-PATH730>3.0.CO;2-O     Document Type: Article

References (38)

1. Bártek J, Iggo R, Gannon J, Lane DP. Genetic and immunochemical analysis of mutant p53 in human breast cancer cell lines. Oncogene 1990; 5: 893-899.
2. Bodner SM, Minna JD, Jensen SM, et al. Expression of mutant p53 proteins in lung cancer correlates with the class of p53 gene mutation. Oncogene 1992; 7: 743-749.
3. Vojtesek B, Bártek J, Midgley CA, Lane DP. An immunochemical analysis of the human nuclear phosphoprotein p53. J Immunol Methods 1992; 151: 237-244.
4. Oliner JD, Pietenpol JA, Thiagalingam S, Gyuris J, Kinzler KW, Vogelstein B. Oncoprotein MDM2 conceals the activation domain of tumour suppressor p53. Nature 1993; 362: 857-860.
5. Cordon-Cardo C, Latres E, Drobnjak M, et al. Molecular abnormalities of mdm2 and p53 genes in adult soft tissue sarcomas. Cancer Res 1994; 54: 794-799.
6. Reifenberger G, Liu L, Ichimura K, Schmidt EE, Collins VP. Amplification and overexpression of the MDM2 gene in a subset of human malignant gliomas without p53 mutations. Cancer Res 1993; 53: 2736-2739.
7. Farkharzadeh SS, Trusko SP, George DL. Tumorigenic potential associated with enhanced expression of a gene that is amplified in mouse tumor cell line. EMBO J 1991; 10: 1565-1569.
8. Berberich S, Cole M. The mdm-2 oncogene is translocated and overexpressed in a murine plasmacytoma cell line expressing wild-type p53. Oncogene 1994; 9: 1469-1472.
9. Landers JE, Haines DS, Strauss JF, George DL. Enhanced translation: a novel mechanism of mdm2 oncogene overexpression identified in human tumor cells. Oncogene 1994; 9: 2745-2750.
10. Olson DC, Marechal V, Momand J, Chen J, Romocki C, Levine AJ. Identification and characterization of multiple mdm-2 proteins and mdm-2-p53 protein complexes. Oncogene 1993; 8: 2353-2360.
11. Picksley SM, Vojtesek B, Sparks A, Lane DP. Immunochemical analysis of the interaction of p53 with MDM2; fine mapping of the MDM2 binding site on p53 using synthetic peptides. Oncogene 1994; 9: 2523-2529.
12. Haines DS, Landers JE, Engle LJ, George DL. Physical and functional interaction between wild-type p53 and mdm2 proteins. Mol Cell Biol 1994; 14: 1171-1178.
13. Leng P, Brown DR, Shivakumar CV, Deb S, Deb SP. N-terminal 130 amino acids of MDM2 are sufficient to inhibit p53-mediated transcriptional activation. Oncogene 1995; 10: 1275-1282.
14. Leach FS, Tokino T, Meltzer P, et al. p53 mutation and MDM2 amplification in human soft tissue sarcomas. Cancer Res 1993; 53: 2231-2234.
15. Weiss SW, Rao VK. Well-differentiated liposarcoma (atypical lipoma) of deep soft tissue of the extremities, retroperitoneum, and miscellaneous sites. A follow-up study of 92 cases with analysis of the incidence of 'dedifferentiation'. Am J Surg Pathol 1992; 16: 1051-1058.
16. Evans HL, Soule EH, Winkelmann RK. Atypical lipoma, atypical intramuscular lipoma, and well differentiated retroperitoneal liposarcoma. A reappraisal of 30 cases formerly classified as well differentiated liposarcoma. Cancer 1979; 43: 574-584.
17. Evans HL. Liposarcomas and atypical lipomatous tumours: a study of 66 cases followed for a minimum of 10 years. Surg Pathol 1988; 1: 41-54.
18. Mandahl N, Mertens F, Willen H, Rydholm A, Brosjo O, Mitelman F. A new cytogenetic subgroup in lipomas: loss of chromosome 16 material in spindle cell and pleomorphic lipomas. J Cancer Res Clin Oncol 1994; 120: 707-711.
19. Evans HL, Khurana KK, Kemp BL, Ayala AG. Heterologous elements in the dedifferentiated component of dedifferentiated liposarcoma. Am J Surg Pathol 1994; 18: 1150-1157.
20. Cattoretti G, Becker MHG, Key G, et al. Monoclonal antibodies against recombinant parts of the Ki-67 antigen (MIB 1 and MIB 3) detect proliferating cells in microwave processed formalin-fixed paraffin sections. J Pathol 1992; 168: 357-363.
21. Oliner JD, Kinzler KW, Meltzer PS, George DL, Vogelstein B. Amplification of a gene encoding a p53-associated protein in human sarcomas. Nature 1992; 358: 80-83.
22. Gaidano G, Ballerini P, Gong JZ, et al. p53 mutations in human lymphoid malignancies: association with Burkitt lymphoma and chronic lymphocitic leukemia. Proc Natl Acad Sci USA 1991; 88: 5413-5417.
23. Donghi R, Longoni A, Pilotti S, Michieli P, Della Porta G, Pierotti MA. Gene p53 mutations are restricted to poorly differentiated and undifferentiated carcinomas of the thyroid gland. J Clin Invest 1993; 91: 1753-1760.
24. Miozzo M, Sozzi G, Calderone C, et al. t(11;22) in three cases of peripheral neuroepithelioma. Genes Chrom Cancer 1990; 2: 163-165.
25. Mitelman F, Karger S. ISCN: Guidelines for Cancer Cytogenetics. Supplement to An International System for Human Cytogenetic Nomenclature. Basel: 1991.
26. Pinkel D, Straume T, Gray JW. Cytogenetic analysis using quantitative, high-sensitivity, fluorescence hybridization. Proc Natl Acad Sci USA 1986; 83: 2934-2938.
27. Sozzi G, Minoletti F, Miozzo M, et al. Relevance of cytogenetic and FISH analyses in the clinical assessment of soft tissue sarcoma. Hum Pathol (in press).
28. Nakayama T, Toguchida J, Wadayama B, Kanoe H, Kotoura Y, Sasaki MS. MDM2 gene amplification in bone and soft-tissue tumors: association with tumor progression in differentiated adipose-tissue tumors. Int J Cancer 1995; 64: 342-346.
29. Meltzer PS. MDM2 and p53: a question of balance. J Natl Cancer Inst 1994; 86: 1265-1266.
30. Shimoda T, Yamashita H, Furusato M, et al. Liposarcoma. A light and electron microscopic study with comments on their relation to malignant fibrous histiocytoma and angiosarcoma. Acta Pathol Jpn 1980; 30: 779-797.
31. Florenes VA, Moelandsmo GM, Forus A, Andreassen A, Myklebost O, Fodstad O. MDM2 gene amplification and transcript levels in human sarcomas: relationship to TP53 gene status. J Natl Cancer Inst 1994; 86: 1297-1302.
32. Kindblom LG, Angervall L, Svendsen P. Liposarcoma. A clinicopathologic, radiographic and prognostic study. Acta Pathol Microbiol Scand 1975; 253(Suppl): 5-71.
33. Lucas DR, Nascimento AG, Sanjay BKS, Rock MG. Well-differentiated liposarcoma. The Mayo Clinic experience with 58 cases. Am J Clin Pathol 1994; 102: 677-683.
34. Nilbert M, Rydholm A, Willen H, Mitelman F, Mandahl N. MDM2 gene amplification correlates with ring chromosomes in soft tissue tumors. Genes Chrom Cancer 1994; 9: 261-265.
35. Pedeutour F, Suijkerbuijk RF, Forus A, et al. Complex composition and co-amplification of SAS and MDM2 in ring and giant rod marker chromosomes in well-differentiated liposarcoma. Genes Chrom Cancer 1994; 10: 85-94.
36. Suijkerbuijk RF, Sinke RJ, Olde Weghuis DEM, et al. Amplification of chromosome subregion 12p11.2-p12.1 in a metastasis of an I(12p)-negative seminoma: relationship to tumor progression? Cancer Genet Cytogenet 1994; 78: 145-152.
37. Chen C-Y, Oliner JD, Zhan Q, Fornace AJ, Vogelstein B, Kastan MB. Interactions between p53 and MDM2 in a mammalian cell cycle checkpoint pathway. Proc Natl Acad Sci USA 1994; 91: 2684-2688.
38. Gibas Z, Miettinen M, Limon J, et al. Cytogenetic and immunohistochemical profile of myxoid liposarcoma. Am J Clin Pathol 1995; 103: 20-26.